Results of a randomized, placebo‐controlled phase 1b study in MCI and mild AD patients with the orally available PRI‐002 with a unique mode of action.

PRI-002 was well tolerated. No biomarker changes have been found after 28 days of treatment. No ARIA were detected. Memory improved significantly in the verum group. The randomized, double-blind, placebo-controlled PRImus-AD phase 2 study has finished recruiting to assess safety and efficacy of PRI-002 in patients with MCI and mild dementia due to AD (EU CT# 2022-503148-41).

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70859_101508
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Results of a randomized, placebo‐controlled phase 1b study in MCI and mild AD patients with the orally available PRI‐002 with a unique mode of action.

Dagmar Jürgens, Gunther Kauselmann, Janine Kutzsche, Nicoleta Carmen Cosma et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

Results of a randomized, placebo‐controlled phase 1b study in MCI and mild AD patients with the orally available PRI‐002 with a unique mode of action.

Dagmar Jürgens, Gunther Kauselmann, Janine Kutzsche, Nicoleta Carmen Cosma, Dieter Willbold, Oliver Peters
article en

Abstract

PRI-002 was well tolerated. No biomarker changes have been found after 28 days of treatment. No ARIA were detected. Memory improved significantly in the verum group. The randomized, double-blind, placebo-controlled PRImus-AD phase 2 study has finished recruiting to assess safety and efficacy of PRI-002 in patients with MCI and mild dementia due to AD (EU CT# 2022-503148-41).

Alzheimer s & DementiaVol. 21(S5)
Forschungszentrum Jülich (DE), Humboldt-Universität zu Berlin (DE), Stadtwerke Jülich (Germany) (DE), Ministerium für Verkehr des Landes Nordrhein-Westfalen (DE), Heinrich Heine University Düsseldorf (DE), Franklin University (US), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 33%
Alzheimer's disease research and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Results of a randomized, placebo‐controlled phase 1b study in MCI and mild AD patients with the orally available PRI‐002 with a unique mode of action. — Dagmar Jürgens, Gunther Kauselmann, et al. · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS